Introduction
Peptic ulceration is common in chronic renal failure. After renal transplantation the risk of upper gastrointestinal bleeding increases considerably. The incidence is 5-12%,'-5 and because mortality in patients in whom it develops is above 500o prophylactic gastric surgery has been considered.' The reason for the increase in bleeding episodes is uncertain. Chisholm et al found a significant increase in peak acid output in men after renal transplantation but not in women. 4 The increase was not related to the steroid dose, the presence of hyperparathyroidism, or the severity of the previous uraemia. They concluded that prophylactic surgery was not indicated. Conversely, Doherty suggested that upper gastrointestinal bleeding after renal transplantation could be prevented if steroids were used more sparingly, but he gave no information on the effect on secretion of acid. 6 Histamine H2 receptor antagonists are potent inhibitors of secretion of gastric acid and might prove useful in preventing upper gastrointestinal bleeding after renal transplantation. The aim of this prospective study was to assess the effects of cimetidine on upper gastrointestinal bleeding after renal transplantation and on allograft function and the incidence of rejection.
Patients and methods
Ninety seven patients consecutively admitted for renal transplantation ( 
Severe upper gastrointestinal bleeding occurred in 12 patients (seven men, five women). None of them had a history of peptic ulcer, and the examinations of the upper gastrointestinal tract before transplantation had yielded normal results. During the acute bleeding episode six of these patients were examined either radiographically or endoscopically. Two had an acute gastric ulcer, and four had diffuse bleeding from gastric or duodenal erosions. Eleven patients had received placebo and one cimetidine. This difference was significant (x2 7.07, p <0 01). All bleeding episodes occurred within the first 30 days after renal transplantation (median 12, range 1-30 days).
Ten patients given placebo and 12 given cimetidine had their renal graft removed after five to 145 (median 35) days because of rejection. This difference was not significant (X2-0 167).
Discussion
Only a few, retrospective studies of the prophylactic use of cimetidine in renal transplant recipients have been reported. These have compared the incidence of upper gastrointestinal haemorrhage in patients treated with cimetidine with that in historic controls not receiving cimetidine. In such retrospective studies Jones et al and Roermund et al found a significant effect of cimetidine7 8 and Garvin et al reported some effect.9 In the only prospective study reported Schiessel et al found no significant effect of cimetidine after renal transplantation in 55 patients. 10 Primack suggested that treatment with cimetidine might increase the incidence of allograft rejection."1 Schiessel et al did not confirm this. 10 Our study showed that in most patients cimetidine prevents upper gastrointestinal bleeding after renal transplantation. This accords with the results of the previous retrospective studies. In the prospective study of Schiessel et al three patients given cimetidine and two given placebo had upper gastrointestinal bleeding.'0 The apparent difference between these findings and those of our study may be explained by the different number of patients studied.
In conclusion, our study showed that cimetidine acts as effective and safe prophylaxis against upper gastrointestinal bleeding after renal transplantation. There was no indication that it influenced the incidence of rejection of the renal graft.
Introduction
Serious allergic reactions to aprotinin occur in less than 0 1 % of patients receiving this drug.' We report on a man who, despite negative ocular sensitivity tests, had a severe anaphylactic reaction after the intravenous administration of aprotinin.
Case report A 44 year old man with a clinical history suggestive of chronic pancreatitis secondary to alcohol abuse was referred to this hospital for endoscopic retrograde pancreatography.
He gave a history of having been admitted several times to the referring hospital with upper abdominal pain, often associated with appreciable hyperamylasaemia. He was usually treated conservatively with intravenous fluids and analgesics and according to the records had twice received an infusion of aprotinin. In June 1982 he had undergone suction drainage of a ruptured pancreatic pseudocyst, after which he had further episodes of abdominal pain, often necessitating admission to hospital and treatment with narcotic analgesics.
Recent investigations had shown normal haematology and biochemistry. Ultrasound scanning of the pancreas showed some dense echoes in the head and body; the tail, however, could not be clearly defined. A Lundh test meal was indicative of early pancreatic insufficiency.
Our policy with patients undergoing endoscopic retrograde pancreatography who have a history of pancreatitis was to administer 500 000 Kallikrein inhibiting units (KIU) aprotinin intravenously,
